C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 316—Orphan DrugsSubpart C—Designation of an Orphan Drug

21 C.F.R. § 316.20 (2026)

Content and format of a request for orphan-drug designation

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 2 IN 5Y cited 2014–2025 6citing cases
At a glance

Courts have cited this section in 6 opinions since 2014, 2 of them in the last five years. The most litigated part is subsection (a) (1 case).

(a) A sponsor that submits a request for orphan-drug designation of a drug for a specified rare disease or condition shall submit each request in the form and containing the information required in paragraph (b) of this section. A sponsor may request orphan-drug designation of a previously unapproved drug, or of a new use for an already marketed drug. In addition, a sponsor of a drug that is otherwise the same drug as an already approved drug may seek and obtain orphan-drug designation for the subsequent drug for the same rare disease or condition if it can present a plausible hypothesis that its drug may be clinically superior to the first drug. More than one sponsor may receive orphan-drug designation of the same drug for the same rare disease or condition, but each sponsor seeking orphan-drug designation must file a complete request for designation as provided in paragraph (b) of this section.

(b) A sponsor shall submit two copies of a completed, dated, and signed request for designation that contains the following:

(1) A statement that the sponsor requests orphan-drug designation for a rare disease or condition, which shall be identified with specificity.

(2) The name and address of the sponsor; the name of the sponsor's primary contact person and/or resident agent including title, address, telephone number, and email address; the generic and trade name, if any, of the drug, or, if neither is available, the chemical name or a meaningful descriptive name of the drug; and the name and address of the source of the drug if it is not manufactured by the sponsor.

(3) A description of the rare disease or condition for which the drug is being or will be investigated, the proposed use of the drug, and the reasons why such therapy is needed.

(4) A description of the drug, to include the identity of the active moiety if it is a drug composed of small molecules, or of the principal molecular structural features if it is composed of macromolecules; its physical and chemical properties, if these characteristics can be determined; and a discussion of the scientific rationale to establish a medically plausible basis for the use of the drug for the rare disease or condition, including all relevant data from in vitro laboratory studies, preclinical efficacy studies conducted in an animal model for the human disease or condition, and clinical experience with the drug in the rare disease or condition that are available to the sponsor, whether positive, negative, or inconclusive. Animal toxicology studies are generally not relevant to a request for orphan-drug designation. Copies of pertinent unpublished and published papers are also required.

(5) Where the sponsor of a drug that is otherwise the same drug as an already approved drug seeks orphan-drug designation for the subsequent drug for the same rare disease or condition, an explanation of why the proposed variation may be clinically superior to the first drug.

(6) Where a sponsor requests orphan-drug designation for a drug for only a subset of persons with a particular disease or condition that otherwise affects 200,000 or more people (“orphan subset”), a demonstration that, due to one or more properties of the drug, the remaining persons with such disease or condition would not be appropriate candidates for use of the drug.

(7) A summary of the regulatory status and marketing history of the drug in the United States and in foreign countries, e.g., IND and marketing application status and dispositions, what uses are under investigation and in what countries; for what indication is the drug approved in foreign countries; what adverse regulatory actions have been taken against the drug in any country.

(8) Documentation, with appended authoritative references, to demonstrate that:

(i) The disease or condition for which the drug is intended affects fewer than 200,000 people in the United States or, if the drug is a vaccine, diagnostic drug, or preventive drug, the persons to whom the drug will be administered in the United States are fewer than 200,000 per year as specified in § 316.21(b), or

(ii) For a drug intended for diseases or conditions affecting 200,000 or more people, or for a vaccine, diagnostic drug, or preventive drug to be administered to 200,000 or more persons per year in the United States, there is no reasonable expectation that costs of research and development of the drug for the indication can be recovered by sales of the drug in the United States as specified in § 316.21(c).

(c) Any of the information previously provided by the sponsor to FDA under subpart B of this part may be referenced by specific page or location if it duplicates information required elsewhere in this section.

[57 FR 62085, Dec. 29, 1992, as amended at 78 FR 35133, June 12, 2013]
The 6 cases that cite 21 C.F.R. § 316.20 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENEagle Pharm., Inc. v. Alex Azar, II, 952 F.3d 323 (D.C. Cir. 2020).
cites § 316.20 3×subsections: (a)cited by 34 cases
Where it cites § 316.20
“” 21 C.F.R. § 316.20 (b)(4). Essentially, FDA believed that before designating an as yet undeveloped drug, it would need reason to believe that the drug might work as intended to treat an orphan disease.”
The case’s holding
The agency cannot impose additional requirements beyond statutory criteria for granting marketing exclusivity to a drug designated and approved under the Orphan Drug Act.
Later courts cite it for
“the text leaves no room for the fda to place additional requirements on a drug that has been designated and approved before granting its manufacturer the right to exclusivity.” · 2 citing courts
2
cites § 316.20 3×cited by 11 cases
Where it cites § 316.20
“§ 360bb and 21 C.F.R. § 316.20 . (SAR, ECF No. 18, at 4.”
3
GREENBraeburn Inc. v. U.S. Food & Drug Admin., 389 F. Supp. 3d 1 (D.C. Cir. 2019).
cites § 316.20 1×cited by 6 cases
Where it cites § 316.20
“" 21 C.F.R. § 316.20 (a). Orphan-designated drugs receive 7-year exclusivity periods under the conditions set forth in 21 U.”
4
GREENJazz Pharm., Inc. v. Robert F. Kennedy Jr., 141 F.4th 254 (D.C. Cir. 2025).
cites § 316.20 2×cited by 1 case
Where it cites § 316.20
“21 C.F.R. §§ 316.20 (a), 316.25(a)(3). Second, at the approval stage, the FDA will grant orphan-drug exclusivity after a drug has received marketing approval under 21 U.”
Later courts cite it for
“the words of a statute must be read in their context and with a view to their place in the overall statutory scheme.” · 2 citing courts
5
NO FLAGBraeburn Inc. v. United States Food & Drug Admin., No. 2019-0982 (D.D.C. July 22, 2019).
cites § 316.20 1×cited by 0 cases
Where it cites § 316.20
“” 21 C.F.R. § 316.20 (a). Orphan-designated drugs receive 7-year exclusivity periods under the conditions set forth in 21 U.”
6
NO FLAGNeurelis Inc. v. Califf, No. 2024-1576 (D.D.C. Feb. 14, 2025).
cites § 316.20 1×cited by 0 cases
Where it cites § 316.20
“AR19 (citing 21 CFR § 316.20 (a)). Neurelis successfully did so based on a showing that drug delivery through a nasal spray provided a major contribution to patient care over a rectal gel.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
201420192025

One bar per year. Tallest: 2 cases in 2019. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.C. Cir.3D.D.C.3
By subsection
(a)1 case
Eagle Pharm., Inc. v. Alex Azar, II, 952 F.3d 323 (D.C. Cir. 2020).“” 21 C.F.R. § 316.20 (b)(4). Essentially, FDA believed that before designating an as yet undeveloped drug, it would need reason to believe that the drug might work as intended to treat an orphan disease.”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com